OBJECTIVE: To determine the metabolic and health effects of chronic consumption of high-fructose corn syrup (HFCS), sucrose and honey in individuals with normal glucose tolerance (GT) and impaired glucose tolerance (IGT).
OBJECTIVE: To determine whether healthy humans can adequately compensate for sugar-sweetened beverage (SSB) calorie intake through reductions in solid food intake, and whether fructose content affects the degree of compensation.
OBJECTIVE: To summarise the epidemiological and clinical trial evidence evaluating the relationship between fructose, especially fructose-containing beverages (SSB), and risk of obesity, diabetes and cardiovascular disease (CVD) in adults. To address potential biological mechanisms with an emphasis on fructose physiology, to consider healthier alternatives to SSBs and potential approaches to reducing SSB intake.
OBJECTIVE: To assess the effect of fructose on established therapeutic lipid targets for cardiovascular disease through a systematic review and meta-analysis of controlled clinical trials.
OBJECTIVE: To define what has been learned over the past 10 years – what questions have been answered and what new questions have arisen – regarding the role of fructose-containing caloric sweeteners (FCCS) and sugar-sweetened beverages (SSBs), and a potential causal role in the development of metabolic diseases.
DESIGN: Review/position paper, based on relevant meta-analyses and critical systematic reviews published between 2007 and February 2015. More “Health effects of fructose and fructose-containing caloric sweeteners: where do we stand 10 years after the initial whistle blowings?”
OBJECTIVE: To determine the dose-response effects of consuming beverages with different concentrations of high fructose corn syrup (HFCS) on risk markers for cardiovascular disease (CVD) and uric acid. More “A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults”
OBJECTIVE: To examine temporal trends of fructose dose in human controlled feeding trials of fructose and cardiometabolic risk. More “The ecologic validity of fructose feeding trials: supraphysiological feeding of fructose in human trials requires careful consideration when drawing conclusions on cardiometabolic risk”
OBJECTIVE: To explore associations between fructose intake and NAFLD, measured by the Fatty Liver Index (FLI) and the NAFLD liver fat score on the basis of blood measurements, in a cohort of ~2000 older adults.
OBJECTIVE: To review the biochemistry of fructose as it interacts with glucose and glucose homeostasis. Particular attention to be made to processes that occur when amounts of fructose are consumed reflective of normal human diets.
More “Normal Roles for Dietary Fructose in Carbohydrate Metabolism”
OBJECTIVE: To explore dose response effects on the metabolism and impact on CHD risk factors of sucrose and high fructose corn syrup (HFCS), at doses of 8% of calories required for weight maintenance (upper level recommended by the American Heart Association (AHA) and WHO), 18% of calories (~ average consumption in USA), and 30% of calories (~Institute of Medicine (IOM) and Dietary Guidelines for Americans (DGAs) upper limit). Doses represented 25th, 50th and 90th percentile population consumption levels of fructose in the American population.